Drupal-Biblio17<style face="normal" font="default" size="100%">Prion-like propagation of post-translationally modified tau in alzheimer's disease: a hypothesis</style>Drupal-Biblio17<style face="normal" font="default" size="100%">Baicalein suppresses repeat tau fibrillization by sequestering oligomers</style>Drupal-Biblio17<style face="normal" font="default" size="100%">Protein-capped metal nanoparticles inhibit tau aggregation in alzheimer's disease</style>Drupal-Biblio17<style face="normal" font="default" size="100%">EGCG impedes human Tau aggregation and interacts with Tau</style>Drupal-Biblio17<style face="normal" font="default" size="100%">P301 L, an FTDP-17 mutant, exhibits enhanced glycation in vitro</style>Drupal-Biblio17<style face="normal" font="default" size="100%">Residue-based propensity of aggregation in the Tau amyloidogenic hexapeptides AcPHF6*and AcPHF6</style>Drupal-Biblio17<style face="normal" font="default" size="100%">Baicalein inhibits heparin-induced Tau aggregation by initializing non-toxic Tau oligomer formation</style>Drupal-Biblio17<style face="normal" font="default" size="100%">Epigallocatechin-3-gallate modulates tau post-translational modifications and cytoskeletal network</style>Drupal-Biblio17<style face="normal" font="default" size="100%">Extracellular HDAC6 ZnF UBP domain modulates the actin network and post-translational modifications of Tau</style>Drupal-Biblio17<style face="normal" font="default" size="100%">Inhibitory effect of curcumin-artemisinin co-amorphous on Tau aggregation and Tau phosphorylation</style>Drupal-Biblio17<style face="normal" font="default" size="100%">Dual modification of tau by pseudophosphorylation and glycation does not enhance amorphous aggregation</style>